Hodgkin's Lymphoma News

• Non-AIDS Cancers Expected to Dominate in HIV-infected Adults by 2030
  Reuters Health Information, May 2018
• EU OK for Generic Carmustine for Brain Tumors and Lymphoma A generic version of carmustine has been recommended for approval in the European Union, as have indication extensions for several cancer drugs.
  Medscape Medical News, April 2018
• After 1400% Price Hike, Generic Cancer Drug in Spotlight Skyrocketing prices for some generic drugs have garnered increased attention, and lomustine is the latest to be scrutinized by the federal government
  Medscape Medical News, April 2018
• Alert FDA Approval Tweaks Decades-Old Treatment of Hodgkin's Lymphoma The approval adds to the indications with which brentuximab can used in the treatment of classic Hodgkin's lymphoma.
  FDA Approvals, March 2018
• AACR 2018Successful CAR T-Cell Tx Needs Good T Cells to Begin With Starting with poor-quality T cells may be a key problem in the manufacturing of effective and functional CAR T cells, which may explain why it has been difficult to apply this approach to all cancers.
  Medscape Medical News, March 2018
• For Cancer, Cannabis Has Many Virtues, Says Large Study It's an observational study and cannot demonstrate causality, but new data from Israel indicate that cannabis may improve a range of common symptoms among cancer patients.
  Medscape Medical News, March 2018
• Cancer Survival Unaffected by England's National Cancer Plan Overall short-term cancer survival and socioeconomic inequalities seem to have been unaffected by a 5-year national cancer initiative in England to boost care delivery.
  Medscape Medical News, March 2018
• CSSIncreased Risk for CVD in Some Cancer Survivors Now that cancer survivors are living longer, other health concerns, such as cardiovascular disease (CVD), become of concern.
  Medscape Medical News, February 2018
• New Guidelines for Treating Checkpoint Inhibitor Toxicities ASCO and the NCCN have issued joint guidelines for treating toxicities associated with checkpoint inhibitor treatment.
  Medscape Medical News, February 2018
• CSSNo Follow-up in More Than a Third of AYA Cancer Survivors A large proportion of adolescent and young adult (AYA) cancer survivors are not receiving follow-up care after the end of their active treatment.
  Medscape Medical News, February 2018
• After Lymphoma, Risk for Breast Cancer Differs by Subtype The risk of developing estrogen-receptor-negative breast cancer following Hodgkin's lymphoma is increased regardless of prior radiotherapy.
  Medscape Medical News, January 2018
• ASHFirst in 30 Years: Improved Front Line in Hodgkin's Lymphoma Brentuximab vedotin has already made an impact on the management of relapsed/refractory classical Hodgkin's lymphoma. Now the drug is poised for frontline use.
  Medscape Medical News, December 2017
• Living in Very Cold Climate and Increased Cancer Risk A study demonstrating the environmental impact on natural selection of genetic variants for survival supports a 'long-standing' hypothesis about the origins of cancer.
  Medscape Medical News, December 2017
• Alert EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents The Committee for Medicinal Products for Human Use has issued a new list of recommendations and rejections for oncology products.
  International Approvals, November 2017
• Anti-TNF Agents, Thiopurines Increase Lymphoma Risk in IBD Thiopurines and anti-TNF agents were associated with a small but significant increase in the risk for lymphoma in patients with IBD, particularly when used in combination, a study has found.
  Medscape Medical News, November 2017
• Neurologic AEs on Rise as Checkpoint Inhibitors Evolve Potentially lethal immune-related adverse events (AEs) are expected to increase as anti-PD-1 therapies for solid tumors expand to include other cancers.
  Medscape Medical News, September 2017
• Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era?
  Reuters Health Information, August 2017
• Immunotherapy in Cancer: Hits and Misses, but Charging Ahead Immunotherapy in cancer care has taken off, but recent negative trials and limited success have raised some criticism and concern.
  Medscape Medical News, August 2017
• Proton Therapy Insurance Coverage: Fair or Foul? At one center, the vast majority of requests for coverage for treatment of a set of cancers were approved, although some approvals required going through an appeal process. But was this well done?
  Medscape Medical News, August 2017
• Immune Checkpoint Inhibitors Effective for Advanced Urothelial, Renal Cancers In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors (ICIs) are more effective and safer than conventional second-line treatment, a new systematic review from The Netherlands reports.
  Reuters Health Information, July 2017